What is Immunocore?
Immunocore is a British clinical-stage biotechnology firm founded in 2008, specializing in the development of innovative biological drugs. The company leverages its proprietary soluble T-cell receptor technology to address critical unmet needs in oncology, infectious diseases, and autoimmune diseases. Its focus on cutting-edge therapeutic modalities positions it as a key player in the biopharmaceutical landscape, aiming to transform treatment paradigms for severe conditions.
How much funding has Immunocore raised?
Immunocore has raised a total of $822.1M across 4 funding rounds:
Series A
$320M
Series B
$130M
Series C
$75M
Stock Offering
$297.1M
Series A (2015): $320M with participation from woodford investment management, Malin Corporation plc, eli lilly and company, and RTW Funds
Series B (2020): $130M led by WuXi AppTec, Rock Springs Capital, General Atlantic LLC, Eli Lilly and Company, JDRF T1D Fund, Terra Magnum Capital Partners, Bill & Melinda Gates Foundation, RTW Investments, and China Construction Bank
Series C (2021): $75M supported by BlackRock
Stock Issuance/Offering (2021): $297.1M, investors not publicly disclosed
Key Investors in Immunocore
WuXi AppTec
WuXi AppTec is a global pharmaceutical and medical device open-access capability and technology platform company, offering a broad range of R&D and manufacturing services that enable companies in the life sciences industry to discover, develop and manufacture their products.
Rock Springs Capital
Rock Springs Capital is a Texas-based investment firm with a focus on real estate, but its participation suggests a diversified investment strategy or a specific interest in the company's growth potential.
General Atlantic LLC
General Atlantic is a global growth equity firm that provides capital and strategic support to high-growth companies, indicating a focus on scaling and market expansion for Immunocore.
What's next for Immunocore?
The substantial enterprise-level funding and recent strategic investment indicate Immunocore is poised for significant expansion and advancement of its clinical pipeline. This capital infusion will likely accelerate the progression of its drug candidates through late-stage clinical trials, support manufacturing scale-up, and potentially facilitate global commercialization efforts. The company's trajectory suggests a move towards becoming a leading therapeutic provider in its specialized disease areas.
See full Immunocore company page
